A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMGN632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia

Background: Overexpression of CD123 is characteristic of a number of hematological malignancies, including acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). IMGN632 is a CD123-targeting antibody-drug conjugate (ADC) with a novel anti-CD123 antibody coupled to a u...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.4440-4440
Hauptverfasser:	Daver, Naval, Aribi, Ahmed, Montesinos, Pau, Roboz, Gail J., Wang, Eunice S., Walter, Roland B., Jeyakumar, Deepa, DeAngelo, Daniel J., Erba, Harry P., Advani, Anjali, Burke, Patrick W., Martinelli, Giovanni, Gastaud, Lauris, Thomas, Xavier, Altman, Jessica K., Mendez, Lourdes M., de la Fuente, Adolfo, Todisco, Elisabetta, Gaidano, Gianluca, Curti, Antonio, Boissel, Nicolas, Recher, Christian, Schliemann, Christoph, Sloss, Callum M, Wang, Jiuzhou, Malcolm, Kara E, Zweidler-McKay, Patrick A, Sweet, Kendra
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!